At a time of geopolitical unrest, market unease and investment uncertainty, understanding and sourcing the right finance to move your respiratory technology from bench to market can feel daunting. Whether you are developing a novel inhaled therapy, a smarter dry powder inhaler or a connected nebulizer, the question is the same: which money, when, and at what cost?
As we look forward to our novel DDL Incubator titled ‘Investing in Inhalation Innovation’, we review the challenges, considerations and opportunities associated with each funding route.
The current funding climate
The good news is that respiratory innovators can still raise capital. The particular challenge we face today is that the funding environment is more selective, more concentrated and more politically uncertain than it was a few years ago, and that makes access uneven, especially for earlier-stage projects or startups.
Economic volatility and higher interest rates through 2025 made investors more cautious about long duration, high risk assets such as lifesciences R&D. Fundraising cycles lengthened and some planned rounds were derailed. Even though overall biotech financing was relatively strong in dollar terms, capital has not flowed evenly, indeed commentators refer to tightened financing and liquidity traps.
A narrowing IPO window
US biotech IPO activity dropped sharply in 2025, with only a handful of companies raising more than $50 million. In the UK and Europe, public markets are an even clearer weak spot, with reports of three consecutive years without a UK biotech IPO. That means specifically for UK respiratory start-ups, you cannot count on a listing to refinance your pipeline, you need to stretch private capital further and think creatively about structure. Meanwhile biotech IPO activity across the APAC region has experienced a notable rebound, driven heavily by Hong Kong’s market leadership. This rebound is characterised by a strong first half of the year, followed by an environment where investors are increasingly selective.
The rising gap between ‘haves and have nots’
Capital is concentrating into fewer, larger mega rounds for later stage, clinically validated assets, which is resulting in a widening gap between those and early and mid-stage companies. Those companies or projects with strong validation still attract oversubscribed rounds while less proven platforms can struggle to secure any institutional funding at all.
Policy uncertainty and competition for capital
Proposed cuts to FDA budgets and, therefore staff, and contentious drug-pricing initiatives, are cited as major obstacles to financing confidence. Meanwhile, the industry is also competing with artificial intelligence, which absorbed an estimated 80% of global venture capital in just one quarter recently. Add to that the reductions in public research funding, and fundraising is becoming a fulltime job for founders, with investors wanting more third-party validation before they commit.
Your funding options at a glance
The table below, kindly supplied by one of our speakers, Chris Hall of Shallcross Partners, provides a practical overview of the funding options. In our Hub we will discuss in more detail those options highlighted in bold.
| Funding route | What it is | Positives | Negatives |
| Bootstrapping | Self-funding through personal resources or early revenue | Full control; no dilution; fast decisions | Limited capital; personal financial risk; slower scaling |
| Friends & family | Early money from personal contacts | Quick access; flexible terms; early validation | Relationship risk; limited strategic input |
| Grants & public funding | Non-dilutive funding from public or institutional bodies | Non-dilutive; credibility; supports R&D | Slow processes; reporting and admin burden |
| Angel investors | Individuals backing early-stage companies with capital and advice | Mentorship; networks; early-stage expertise | Equity dilution; investor quality varies |
| Seed funds & venture capital | Professional investors funding high-growth start-ups for equity | Large capital; scale quickly; strong signalling | Significant dilution; growth pressure; reduced control |
| Accelerators & incubators | Structured programmes offering mentorship and small funding for equity | Mentorship; investor access; credibility | Equity for small capital; time-intensive |
| Revenue-based financing | Non-equity funding repaid as a percentage of revenue | No dilution; repayments scale with revenue | Requires revenue; cash-flow impact |
| Debt / loans | Borrowed capital repaid with interest | No equity loss; predictable cost | Repayment risk; personal guarantees often required |
| Corporate / strategic investment | Investment from established companies seeking strategic alignment | Market access; industry knowledge; partnerships | Strategic constraints; slower decisions |
| Crowdfunding | Raising from many individuals via online platforms | Validation; marketing exposure; community | Admin complexity; disclosure risk; investor management |
The five routes to focus on
Bootstrapping: buy time and keep control
Bootstrapping means growing the business with personal savings, consulting income and early revenue. It keeps you in full control, but capital is limited and scaling is slow. Many companies bootstrap in a broader sense, stitching together grants, small contracts and shared lab or incubator space to delay dilution. This works best when burn is low, such as a virtual model using CROs, or a narrow device or diagnostic proof-of-concept.
Grants: de-risk the science without giving away equity
Grants don’t need repaying and don’t usually cost equity. The trade-off is slow processes, deliverables, audits and reporting, so you need clear workplans and endpoints. Used well, grants validate your science and de-risk early milestones before a larger equity round.
Angel investors: smart money at the early stage
Angels and family offices, often experienced entrepreneurs or industry executives, bring capital plus networks and domain expertise. For respiratory founders, an angel with inhalation, device or regulatory experience can be worth far more than the cheque. The caveats: you give away equity, and investor quality varies, so choose carefully!
Seed and venture capital: fuel to scale
VC is typically the main source of scale capital once initial technical risk is mitigated, and you need to fund preclinical packages, clinical trials and manufacturing. It offers large sums and strong market signalling, but it is expensive: significant dilution, board oversight, milestone pressure and an expectation of a high value exit. And timing really matters, raising after grants and early data have cleared key inflection points that means a higher valuation and stronger negotiating position.
Corporate and strategic investment: capital plus muscle
Pharma and device companies invest through corporate venture arms, option-to-license and co-development deals, sponsored research and early distribution agreements. For inhalation innovators, a strategic partner can bring formulation, device, regulatory and manufacturing capability that would be costly to build alone. The downside is strategic constraint, slower decisions and careful management of IP and exclusivity.
The typical funding journey
Funding routes are rarely chosen once – they stack up over time. A typical path looks like this:
| Stage | Main investor type | Typical raise |
| Idea / prototype | Bootstrapping | £0–30k |
| MVP and traction | Friends & family | £30–100k |
| Early growth | Grants + angels | £100–250k |
| Scale-up | Seed / Series A VC | £250k–£1m |
| Expansion | Series B+ / strategic | £1m+ |
As you progress your journey, founder ownership can fall from 100% to as little as 10%. That’s why two questions matter at every stage. First, how can you minimise development and scale-up costs while maximising income, to reduce the need for external funding? And second, what do you need to be credible to move to the next step?
What ‘investor ready’ really means
Investor readiness isn’t just having a deck and a good idea. It means your company can withstand professional scrutiny and justify the capital it is asking for, which in practice means fulfilling the following criteria…
- Science and IP de-risking: robust data, not just hypotheses, plus a clear IP and freedom-to-operate position.
- A value inflection map: milestones such as proof-of-concept, safety packages, device verification and clinical readouts, with each injection of capital tied to a point where risk drops and value rises.
- A coherent narrative: connecting unmet respiratory need, your solution, the competitive landscape, the regulatory path and commercial potential.
- Structured operations and governance: a functioning team with defined roles, ready for board oversight and reporting.
- Financial clarity: a realistic burn rate, use of funds, timelines and valuation logic, including dilution and cap table.
- External validation: grants won, accelerator places, KOL support and early partnerships, in other words evidence that others have already tested your claims
The bottom line
The funding environment is tougher than it has been for a while, but it isn’t closed. Respiratory start-ups that combine the right routes in the right order: bootstrapping and grants to prove the science, angels to build momentum, VC to scale and strategic partners to reach patients, will be best placed to secure the capital they need. Start with credibility, protect your equity for as long as you can, and make every raise count.
Want to know more? Join us at our Incubator Hub @DDL 2026. You can register here: https://ddl-conference.com/the-ddl-incubator/


















